Your browser doesn't support javascript.
loading
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
de Jong, Jan; Hellemans, Peter; Jiao, James Juhui; Huang, Yuhan; Mesens, Sofie; Sukbuntherng, Juthamas; Ouellet, Daniele.
Afiliación
  • de Jong J; Janssen Research and Development, LLC, San Diego, CA, USA. JDejong1@its.jnj.com.
  • Hellemans P; Janssen Research and Development, LLC, Beerse, Belgium.
  • Jiao JJ; Janssen Research and Development, LLC, Raritan, NJ, USA.
  • Huang Y; Janssen Research and Development, LLC, Shanghai, China.
  • Mesens S; Janssen Research and Development, LLC, Beerse, Belgium.
  • Sukbuntherng J; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Ouellet D; Janssen Research and Development, LLC, Spring House, PA, USA.
Cancer Chemother Pharmacol ; 81(2): 423, 2018 02.
Article en En | MEDLINE | ID: mdl-29214363
ABSTRACT
The author would like to correct the affiliations and conflict of interest in the publication of the original article. The corrected details are given below for your reading.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancer Chemother Pharmacol Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancer Chemother Pharmacol Año: 2018 Tipo del documento: Article